Msh2loxP/loxP; TgTg(Vil1-cre mice without clinical signs of tumor development (i.e. age <12 weeks) received repeated applications (n = 8, 28-day interval) of anti-PD-L1, anti-LAG-3 (2.5 mg/kg bw, i.p.)or isotype (anti-IgG1, 2.5 mg/kg bw, i.p.). This evidence concerns the gene VIL1 and neoplasm.